Identification of novel biomarkers and therapeutic targets for steatohepatitis and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD): an in silico analysis

被引：0
|
作者：
Maya-Miles, Douglas [1 ,2 ]
Gallego-Duran, Rocio [1 ,2 ]
Munoz Hernandez, Rocio [1 ,2 ]
Rojas, Angela [1 ,2 ]
Gil-Gomez, Antonio [1 ,2 ]
Montero-Vallejo, Rocio [1 ,2 ]
Gato, Sheila [1 ,2 ]
Giraldez-Jimenez, Maria [1 ,2 ]
Ampuero, Javier [1 ,2 ]
Romero Gomez, Manuel [1 ,2 ]
机构：
[1] Univ Seville, Hosp Univ Virgen Rocio, Seliver Grp, Inst Biomed Sevilla IBiS,CSIC, Seville, Spain
[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT014
引用
收藏
页码：S660 / S660
页数：1
相关论文
共 50 条
  • [11] Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
    Rocío Gallego-Durán
    Pablo Cerro-Salido
    Emilio Gomez-Gonzalez
    María Jesús Pareja
    Javier Ampuero
    María Carmen Rico
    Rafael Aznar
    Eduardo Vilar-Gomez
    Elisabetta Bugianesi
    Javier Crespo
    Francisco José González-Sánchez
    Reyes Aparcero
    Inmaculada Moreno
    Susana Soto
    María Teresa Arias-Loste
    Javier Abad
    Isidora Ranchal
    Raúl Jesús Andrade
    Jose Luis Calleja
    Miguel Pastrana
    Oreste Lo Iacono
    Manuel Romero-Gómez
    Scientific Reports, 6
  • [12] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
    Bugianesi, E
    Marzocchi, R
    Villanova, N
    Marchesini, G
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1105 - 1116
  • [13] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Jürgen Kurt Rockstroh
    Current HIV/AIDS Reports, 2017, 14 : 47 - 53
  • [14] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Rockstroh, Juergen Kurt
    CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
  • [15] Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
    Tacke, Frank
    Weiskirchen, Ralf
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [16] Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
    Daher, Saleh
    Cohen, Namma Lev
    Massarwa, Muhammad
    Mahamid, Mahmud
    Nasser, Mira
    Hazou, Wadi
    Oren, Rani
    Safadi, Rifaat
    Khoury, Tawfik
    PLOS ONE, 2018, 13 (11):
  • [17] SARCOPENIA AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH ADVANCED FIBROSIS
    Golabi, Pegah
    Paik, James M.
    Cable, Rebecca
    Racila, Andrei
    Srishord, Manirath
    Younossi, Zobair M.
    HEPATOLOGY, 2021, 74 : 1039A - 1039A
  • [18] Identification of new therapeutic targets for hepatic regenerative medicine in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Hora, Shainan
    Gao, Rong
    Iakovleva, Viktoriia
    Bee, Agnes
    Ong, Leng
    Wuestefeld, Torsten
    JOURNAL OF HEPATOLOGY, 2022, 77 : S730 - S731
  • [19] Melanocortins and Interleukins Contributing to Advanced Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in Patients With BMI ≥ 40
    Baranova, Ancha
    Jarrar, Mohammed
    Moazzez, Amir H.
    Elariny, Hazem
    Abawi, Massih
    Wang, Lei
    Afendy, Arian
    Stepanova, Maria
    Estep, J. M.
    Younossi, Zobair M.
    OBESITY, 2011, 19 : S87 - S87
  • [20] Non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) - A growing epidemic
    South, K
    GASTROENTEROLOGY NURSING, 2006, 29 (02) : 169 - 169
12345